VOYAGER PAD
2020
Vascular Outcomes Study of ASA Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD
In 6,564 patients with peripheral artery disease after lower-extremity revascularisation, rivaroxaban 2.5 mg twice daily plus aspirin reduced acute limb ischaemia, major amputation, myocardial infarction, ischaemic stroke or cardiovascular death compared with aspirin alone.
Result
Efficacy: Composite of acute limb ischaemia, major amputation, MI, ischaemic stroke or CV deathHR 0.85 (95% CI 0.76-0.96) · P = 0.009
Safety: ISTH major bleedingHR 1.42 (95% CI 1.10-1.84)
Below 1 favours rivaroxaban 2.5 mg twice daily plus aspirin, above 1 favours aspirin alone.
Event rates Rivaroxaban 2.5 mg twice daily plus aspirin 17.3% vs aspirin alone 19.9% (composite of acute limb ischaemia, major amputation, MI, ischaemic stroke or CV death)
- Subtopic
- Antithrombotic therapy
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 PAADACC/AHA 2024 PAD
- Source
- Bonaca MP, Bauersachs RM, et al. N Engl J Med. 2020;382(21):1994-2004.doi 10.1056/NEJMoa2000052
Discussion & critique
The benefit is driven largely by acute limb ischaemia while major bleeding rises significantly, so selection by bleeding risk is essential. It is the only positive antithrombotic trial in the post-revascularisation PAD population and anchors dual-pathway inhibition in the guideline.